<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717988</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P1201</org_study_id>
    <nct_id>NCT02717988</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, placebo-controlled, single ascending dose study is designed to demonstrate
      safety, tolerability and pharmacokinetics of SKI-O-703 in healthy volunteers. The results of
      this study will guide selection of dose levels for future multiple dose studies in healthy
      volunteers and adult patients with moderately to severely active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled study in healthy adult volunteers that will be
      conducted to evaluate the safety, tolerability, and pharmacokinetics of ascending single
      doses of SKI-O-703. A total of 48 subjects are planned to participate in 6 cohorts (8
      subjects each). In each cohort, 6 subjects will be randomly assigned to receive SKI-O-703 and
      2 subjects will be randomly assigned to matching placebo. Dosing will be initiated in the 50
      mg dose cohort and sequentially escalated to the 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg
      cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants (Healthy Volunteers) with reported adverse events receiving single dose of SKI-O-703 as assessment of safety and tolerability.</measure>
    <time_frame>28 days</time_frame>
    <description>Safety and tolerability of SKI-O-703 as measured by subject incidence of treatment-related Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time 0 to the last quantifiable concentration (AUC0-t) for estimating the pharmacokinetic parameters of SKI-O-592 (the free base of SKI-O-703) and its metabolites.</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>AUC0-t will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>AUC0-inf will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Days 0 (pre-dose), 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Cmax will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 0 (pre-dose), Day1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Tmax will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (T1/2)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>T1/2 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F) (SKI-O-592, free base of SKI-O-703)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Vd/F will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) (SKI-O-592 only)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>CL/F will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Kel will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>MRT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (Rmet), calculated as AUC0-t (metabolite) / AUC0-t (parent) (metabolites M1, M2 and M4 only).</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing) and post-dose at Days 2, 3 and 4</time_frame>
    <description>Rmet will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (SKI-O-592, free base of SKI-O-703 only)</measure>
    <time_frame>Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Renal clearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug excreted in urine over the collection intervals of 0 to 4 hours (Ae0-4), 4 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 48 hours, and 48 to 72 hours post dose.</measure>
    <time_frame>Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Ae will be reported</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The pharmacodynamics variable will be the change in the percentage of activated gp53/CD63+ basophils and will be evaluated from serial blood samples collected from subjects who have received SKI-O-703 or placebo.</measure>
    <time_frame>Pre-dose, Day 1(dosing) and post-dose at Day 2</time_frame>
    <description>changes in the percentage of activated gp53/CD63+ basophils will be reported</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (2x25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (4x25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (1x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (2x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (3x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (4x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703 capsule</intervention_name>
    <description>SKI-O-703 25 mg capsule or 200 mg capsule without excipient</description>
    <arm_group_label>SKI-O-703 50 mg</arm_group_label>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_label>SKI-O-703 600 mg</arm_group_label>
    <arm_group_label>SKI-O-703 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo 180 mg capsule filled with microcrystalline cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent for participation prior to
             completing any study procedures

          -  Considered by the investigator to be in good health as determined by the absence of
             clinically significant diseases or clinically significant abnormal values as
             determined by a detailed medical history review, complete physical examination, and
             clinical laboratory assessments. Clinical significance for any out-of-range laboratory
             test results will be determined by the principal investigator

          -  Male subjects and female subjects of non-childbearing potential between the ages of 18
             and 55 years, inclusive

          -  Female subjects of non-childbearing potential are those who are surgically sterile at
             least 6 months or postmenopausal at least 2 years and have follicle-stimulating
             hormone serum levels consistent with postmenopausal status.

          -  Male subjects must agree to use a condom with spermicide or abstain from sexual
             intercourse for 90 days after dosing

          -  Male subjects must agree not to donate sperm for 90 days after dosing

          -  Female subjects must have negative serum pregnancy test results at Screening and Day
             -1

          -  Subject must have a body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, and
             weight â‰¥50 kg

          -  Subject must be able to understand the study and any risks to participation and able
             to communicate with the investigator

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder that may put the subject at
             risk if he/she participates in the study, might affect the subject's ability to
             participate in the study, or influence the study results

          -  History or presence of any gastrointestinal, hepatic or renal disease, or any other
             condition known to interfere with the absorption, distribution, metabolism, or
             excretion (ADME) of drugs

          -  Any surgical or medical conditions possibly affecting drug ADME (eg, bariatric
             procedure)

          -  Any medical/surgical procedure or trauma within 4 weeks of Day -1 as determined by the
             investigator

          -  Any clinically significant infection within 3 months of Day -1 as determined by the
             investigator

          -  Any of the following abnormal laboratory values upon repeat testing at Screening or
             check-in:

               -  Hemoglobin &lt;the lower limit of normal (LLN)

               -  Platelet count &lt;LLN

               -  Absolute neutrophil count &lt;LLN or &gt;the upper limit of normal (ULN)

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;ULN

               -  Creatinine or blood urea nitrogen &gt;ULN

               -  Other clinically significant abnormal laboratory results in the opinion of the
                  investigator

          -  Use of concomitant medications from 30 days or 5 half-lives prior to Day -1 (whichever
             is longer), including prescription medications, nutritional supplements, herbal
             remedies, and over-the-counter medications

          -  Receipt of any investigational medication within 30 days or 5 half-lives prior to Day
             -1, whichever is longer

          -  Use of tobacco or nicotine-containing products within 30 days prior to Day -1 and
             through the End-of-Study visit

          -  Use of cytochrome P450 3A isozyme (CYP3A) inducers and inhibitors (including St.
             John's wort) within 30 days of dosing

          -  Food or beverage containing alcohol, grapefruit or grapefruit juice, apple or orange
             juice, vegetables from the mustard green family (eg, kale, broccoli, watercress,
             collard greens, kohlrabi, brussels sprouts, mustard), and charbroiled meats within 1
             week prior to dosing

          -  History of substance abuse, drug addiction, or alcoholism

          -  Positive urine drug or urine alcohol test result at screening or Day -1 or unable to
             abstain from alcohol from 72 hours prior to study entry to the End-of-Study visit

          -  Unable to abstain from caffeine and xanthine-containing products from 72 hours prior
             to dosing through discharge from the study site

          -  Female subjects who are pregnant or lactating or have a positive serum pregnancy test
             result at Screening

          -  Positive test results at Screening for human immunodeficiency virus, hepatitis B
             surface antigen (HBsAg), hepatitis C virus antibody, or hepatitis B core antibody and
             negative for HBsAg

          -  Recent (past 5 years) history of malignancy except successfully treated basal cell
             carcinoma

          -  High blood pressure, defined as &gt;140 millimeters of mercury (mm Hg) systolic blood
             pressure or &gt;90 mm Hg diastolic blood pressure upon repeat confirmation

          -  Cardiac arrhythmias or clinically significant ECG findings upon repeat confirmation by
             the investigator

          -  Corrected QT interval (QTc) &gt;450 milliseconds or deemed clinically significant by the
             investigator

          -  Family history of long QT syndrome

          -  Blood loss or blood donation &gt;450 mL within 4 weeks of study drug dosing

          -  History of sensitivity to drugs with chemical similarity to the study drug, its
             components, or excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>moderately to severely active</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

